NEW YORK (GenomeWeb) – AMRI has announced a strategic alliance with Bruker Daltonics and HighRes Biosolutions to implement new mass spectrometry technology in drug discovery.

AMRI, a contract research organization, will implement Bruker Daltonics' MALDI PharmaPulse system at its Integrated Drug Discovery Center. Under the terms of the alliance, Bruker Daltonics and HighRes will train and consult with AMRI researchers as they develop protocols for high-throughput screening in drug discovery.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.